Skip to content
Screener

Biodesix, Inc. BDSX Q4 2025 Annual earnings

Reported February 26, 2026 · After market close

Revenue$28.8MBeat by $3.0M
EPS-$0.49Beat by $0.56
Revenue estimate$25.7M
EPS estimate-$1.05

Next report

Nov 5, 2026 (In 3 days)
Revenue estimate$27.5M
EPS estimate-$0.75

Financials

Q4 2025

Income statement

See full
Revenue$28.8M+40.8%
Operating income-$2.0M+70.4%
Net income-$4.0M+51.8%
EPS (diluted)-$0.43+58.3%

Balance sheet

See full
Cash & equivalents$19.0M-27.7%
Total debt$72.8M+17.6%
Total equity-$2.5M-112%
Total assets$87.5M-10.0%

Cash flow

See full
Operating cash flow-+100%
CapEx$86.0K-89.7%
Free cash flow-+100%

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$54.1M-75.7%
Enterprise value$107.96M-58.2%
P/S0.6×-2.5×

Profitability

See full
Operating margin-31.5%-8.1pp
Net margin-39.8%-10.1pp
FCF margin-27.4%-10.5pp

Returns & leverage

See full
Current ratio1.9×-0.9×

Segments

By product

See full
Diagnostic Tests$25.1M+46.2%
Development Services$3.6M+11.9%

FAQ

When did Biodesix, Inc. report Q4 2025 earnings?
Biodesix, Inc. (BDSX) reported Q4 2025 earnings on February 26, 2026 after market close.
What were Biodesix, Inc.'s Q4 2025 revenue and EPS?
Biodesix, Inc. reported revenue of $28.8M and eps of $-0.49 for Q4 2025.
Did Biodesix, Inc. beat estimates in Q4 2025?
Revenue beat the consensus estimate of $25.7M by $3.0M. EPS beat the consensus estimate of $-1.05 by $0.56.
How did Biodesix, Inc.'s Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 40.8% from $20.4M a year earlier and eps declined 716.7% from $-0.06.
Where can I find Biodesix, Inc.'s Q4 2025 SEC filings?
You can read the 8-K earnings release (0001193125-26-076521) and the 10-K periodic report (0001193125-26-076547) directly on SEC EDGAR. The filing index links above go to sec.gov.